Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary psilocybin-based therapy for patients with urgent, unmet needs. April 14TH , 2021 – VANCOUVER, BRITISH COLUMBIA, Vancouver, British Columbia – Albert Labs Inc. (“Albert Labs” or the “Company“) is pleased to announce a brokered private placement (the “Brokered Offering”) of up to 16,000…


Previous articleNew England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
Next articlePharmaTher Provides Update on Psychedelic Product Programs